免疫原发耐药的复杂难治性肺癌应对策略  

Countermeasures of Primary Immune Resistance in Refractory Lung Cancer

作　　者：王柯 刘洋 贾蓉 王绎 谢华[2] 周进[2] Wang Ke;Liu Yang;Jia Rong;Wang Yi;Xie Hua;Zhou Jin(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,Sichuan,China;Department of Medical Oncology,Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,Afiliated Cancer Hospital of University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China;School of Clinical Medicine,Chengdu Medical College,Chengdu 610500,Sichuan,China)

机构地区：[1]电子科技大学医学院,成都610054 [2]四川省肿瘤临床医学研究中心,四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院肿瘤内科,成都610041 [3]成都医学院临床医学院,成都610500

出　　处：《肿瘤预防与治疗》2023年第12期998-1002,共5页Journal of Cancer Control And Treatment

基　　金：广东省临床试验协会/中国胸部肿瘤研究协作组和广东省肺癌转化医学重点实验室开放课题(编号:YC20210105);2022CSCO重点项目(编号:Y-2021AST/zd-0119)。

摘　　要：复杂难治性肺癌包含了一大类各种原因引起的诊断治疗困难、生物学背景复杂的肺癌类型。在肺癌免疫治疗中,原发性耐药缺乏预测性、疗效差、进展快,是临床关注的难点问题之一。从耐药机制上分析,原发性耐药可分为内源性、外源性和宿主因素,并根据机制原因不同,分别有相应的耐药应对策略指导临床。本文阐述了复杂难治性肺癌原发耐药的定义,总结了耐药的发生机制,随后重点对耐药的应对策略进行了文献综述,并提出未来可能有价值的研究方向,为更好地理解免疫原发耐药、研究耐药防治策略提供新的思路。Refractory lung cancer refers to a series of lung cancers which are difficult to be diagnosed and treated and with complex biological background caused by various reasons.Primary immune resistance in refractory lung cancer is a difficult clinical concern due to its lack of predictive markers,poor clinical response,and rapid progression.It mainly stems from endogenous factors,exogenous factors and host factors.As for different mechanisms of primary immune resistance,there are different countermeasures to guide clinical practice.This review described the definition,mechanism,solution and prospect of primary immune resistance in refractory lung cancer,and provides novel options to address immune resistance.

关 键 词：肺恶性肿瘤 免疫检查点抑制剂 原发性免疫耐药 肿瘤免疫微环境 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]